Sarepta Therapeutics, Inc. (SRPT)

Market Cap	8.17B
Revenue (ttm)	1.10B
Net Income (ttm)	-690.88M
Shares Out	93.55M
EPS (ttm)	-7.83
PE Ratio	n/a
Forward PE	8.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	723
Open	88.64
Previous Close	88.14
Day's Range	86.28 - 89.01
52-Week Range	55.25 - 159.89
Beta	1.01
Analysts	Strong Buy
Price Target	160.85 (+84.08%)
Earnings Date	Nov 1, 2023

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 1997
• Employees: 1,162
• Stock Exchange: NASDAQ
• Ticker Symbol: SRPT

Financial Performance

In 2022, SRPT's revenue was $933.01 million, an increase of 32.93% compared to the previous year's $701.89 million. Losses were -$703.49 million, 68.0% more than in 2021.

Analyst Forecast

According to 20 analysts, the average rating for SRPT stock is "Strong Buy." The 12-month stock price forecast is $160.85, which is an increase of 84.08% from the latest price.

Price Target

$160.85

(84.08% upside)

Analyst Consensus: Strong Buy